LTRN
Lantern Pharma Inc.
Overview
Lantern Pharma Inc is a Healthcare company operating in Biotechnology with a $49.6M market cap.
LTRN beat consensus EPS by 0.2% in Q1 FY2026, reported May 17, 2026.
17 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2025Earnings2025-11-132 Q&A exchanges
- Q1 FY2025Earnings2025-05-156 Q&A exchanges
- Q4 FY2024Earnings2025-03-274 Q&A exchanges
- Q3 FY2024Earnings2024-11-081 Q&A exchange
- Q1 FY2024Earnings2024-05-091 Q&A exchange
- Q4 FY2023Earnings2024-03-182 Q&A exchanges
- Q3 FY2023Earnings2023-11-092 Q&A exchanges
- Q2 FY2023Earnings2023-08-098 Q&A exchanges
- Q1 FY2023Earnings2023-05-131 Q&A exchange
- Q4 FY2022Earnings2023-03-201 Q&A exchange
- Q3 FY2022Earnings2022-11-075 Q&A exchanges
- Q2 FY2022Earnings2022-08-082 Q&A exchanges
- Q1 FY2022Earnings2022-05-034 Q&A exchanges
- Q4 FY2021Earnings2022-03-105 Q&A exchanges
- Q3 FY2021Earnings2021-11-016 Q&A exchanges
- Q2 FY2021Earnings2021-07-3120 Q&A exchanges
- Q1 FY2021Earnings2021-05-0417 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-17EPS$-0.30 vs $-0.36+16.7%Rev$0 vs ——EODHD
- Q4 FY20252025-12-30EPS$-0.36 vs $-0.46+21.7%Rev$0 vs ——EODHD
- Q3 FY20252025-11-04EPS$-0.39 vs $-0.44+11.4%Rev$0 vs ——EODHD
- Q2 FY20252025-08-12EPS$-0.40 vs $-0.53+24.5%Rev$0 vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.42 vs $-0.43+2.3%Rev$100.7K vs ——EODHD
- Q4 FY20242025-03-16EPS$-0.54 vs $-0.51-5.9%Rev$100.7K vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.42 vs $-0.56+25.0%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.46 vs $-0.55+16.4%Rev$0 vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.51 vs $-0.43-18.6%Rev$0 vs ——EODHD
- Q4 FY20232024-03-17EPS$-0.39 vs $-0.40+2.5%Rev$261.1K vs ——EODHD
- Q3 FY20232023-11-07EPS$-0.29 vs $-0.45+35.6%Rev$0 vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.44 vs $-0.43-2.3%Rev$0 vs ——EODHD
- Q1 FY20232023-05-08EPS$-0.36 vs $-0.48+25.0%Rev$0 vs ——EODHD
- Q4 FY20222023-03-19EPS$-0.31 vs $-0.47+34.0%Rev$0 vs ——EODHD
- Q3 FY20222022-11-06EPS$-0.21 vs $-0.48+56.3%Rev$0 vs ——EODHD
- Q2 FY20222022-08-07EPS$-0.41 vs $-0.52+21.1%Rev$0 vs ——EODHD
- Q1 FY20222022-05-02EPS$-0.38 vs $-0.29-31.0%Rev$0 vs ——EODHD
- Q4 FY20212022-03-09EPS$-0.32 vs $-0.40+20.0%Rev$0 vs ——EODHD
- Q3 FY20212021-10-31EPS$-0.36 vs $-0.27-33.3%Rev$0 vs ——EODHD
- Q2 FY20212021-07-28EPS$-0.21 vs $-0.26+19.2%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-17 | $-0.30 | $-0.36 | +16.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.36 | $-0.46 | +21.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.39 | $-0.44 | +11.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.40 | $-0.53 | +24.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.42 | $-0.43 | +2.3% | $100.7K | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.54 | $-0.51 | -5.9% | $100.7K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.42 | $-0.56 | +25.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.46 | $-0.55 | +16.4% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.51 | $-0.43 | -18.6% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $-0.39 | $-0.40 | +2.5% | $261.1K | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.29 | $-0.45 | +35.6% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.44 | $-0.43 | -2.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.36 | $-0.48 | +25.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-19 | $-0.31 | $-0.47 | +34.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-06 | $-0.21 | $-0.48 | +56.3% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.41 | $-0.52 | +21.1% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-0.38 | $-0.29 | -31.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.32 | $-0.40 | +20.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-10-31 | $-0.36 | $-0.27 | -33.3% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-07-28 | $-0.21 | $-0.26 | +19.2% | $0 | — | — | EODHD |
Source: EODHD. LTRN reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks LTRN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $5.12 | $3.62 | +41.4% | -3.6% | -1.9% |
| Q4 FY2025 | $5.34 | $3.59 | +48.7% | -6.3% | -5.2% |
| Q3 FY2025 | $5.57 | $3.84 | +45.1% | +2.5% | +3.4% |
| Q2 FY2025 | $4.95 | $3.62 | +36.8% | -2.4% | -3.4% |
| Q1 FY2024 | $5.25 | $3.86 | +36.0% | +0.6% | -1.4% |
| Q4 FY2024 | $5.49 | $3.75 | +46.5% | -2.2% | +0.5% |
| Q3 FY2024 | $5.49 | $3.78 | +45.2% | -4.8% | -2.0% |
| Q2 FY2024 | $5.64 | $3.76 | +50.0% | +2.1% | +4.9% |
| Q1 FY2023 | $5.86 | $3.92 | +49.6% | -4.3% | -4.9% |
| Q4 FY2023 | $5.99 | $4.02 | +49.1% | -2.0% | +0.1% |
Guidance change history
Sample- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Panna SharmaCEO9 mo17 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance cut Q2 FY2025
- David R MargraveCFO1 yr 11 mo17 callsCurrentSample
CFO since 2024 • 3/4 beats (75%) • last guidance raise Q1 FY2025
- Kishor G BhatiaChief Scientific Officer1 yr 11 mo6 callsCurrentSample
OTHER_C_SUITE since 2024 • 2/4 beats (50%) • last guidance raise Q1 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LTRN.
$ curl https://api.spokenalpha.com/v1/companies/LTRNFAQ
Frequently asked about LTRN
Where can I find Lantern Pharma Inc.'s (LTRN) earnings call transcripts?
Spoken Alpha indexes LTRN's earnings call transcripts at https://spokenalpha.com/companies/LTRN. Each call links to attributed speakers and parsed analyst Q&A. Lantern Pharma Inc.'s own investor relations page is at https://ir.lanternpharma.com/overview/default.aspx.
When was Lantern Pharma Inc.'s most recent earnings call?
Lantern Pharma Inc. (LTRN) held its most recent earnings call on 2025-11-13, covering fiscal Q3 2025.
What sector is LTRN in?
Lantern Pharma Inc. (LTRN) operates in the Healthcare sector (Biotechnology industry).